| Trial ID: | L2766 |
| Source ID: | NCT06047262
|
| Associated Drug: |
Dapansutrile
|
| Title: |
Dapansutrile in Diabetes and Diabetes-Related Complications - Dapan-Dia
|
| Acronym: |
Dapan-Dia
|
| Status: |
RECRUITING
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: Dapansutrile|DRUG: Placebo
|
| Outcome Measures: |
Primary: Change in HbA1c in blood of patients for dapansutrile compared to placebo, Comparison of change in HbA1c for dapansutrile and placebo, two time assessment at baseline and week 26 | Secondary: Change in HbA1c in blood of patients for dapansutrile compared to placebo, Comparison of change in HbA1c for dapansutrile and placebo, six time assessment at baseline and week 4, 8, 12, 16, 20|Change in fasting plasma glucose for dapansutrile compared to placebo, Comparison of change in fasting plasma glucose for dapansutrile and placebo, seven time assessement at baseline and week 4, 8, 12, 16, 20, 26
|
| Sponsor/Collaborators: |
Sponsor: University Hospital, Basel, Switzerland | Collaborators: European Union (Horizon Europe Programme)|State Secretariat for Education Research and Innovation, Switzerland|Olatec Therapeutics LLC
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
300
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2024-07-09
|
| Completion Date: |
2026-07-31
|
| Results First Posted: |
|
| Last Update Posted: |
2024-08-14
|
| Locations: |
University Hospital Basel, Basel, 4031, Switzerland
|
| URL: |
https://clinicaltrials.gov/show/NCT06047262
|
